NAC Dosing for Trichotillomania and Excoriation Disorder
For both trichotillomania and excoriation disorder in adults, start N-acetylcysteine at 1200 mg/day and titrate up to 2400-3000 mg/day as tolerated, with clinical response typically emerging after 9 weeks of treatment.
Adult Dosing Protocol
The evidence strongly supports a specific titration strategy:
- Starting dose: 1200 mg/day (typically 600 mg twice daily) 1, 2
- Target dose: 2400-3000 mg/day 1, 2
- Titration: Increase gradually as tolerated over the first few weeks
- Duration before assessment: Expect significant improvement after 9 weeks, with full assessment at 12 weeks 2
The landmark randomized controlled trial for trichotillomania used a dosing range of 1200-2400 mg/day and found that 56% of patients were "much or very much improved" compared to 16% on placebo 2. Similarly, the excoriation disorder trial used 1200-3000 mg/day and demonstrated 47% of NAC-treated patients were much or very much improved versus 19% on placebo 1.
Pediatric Dosing
For children and adolescents, begin with 600 mg twice daily (1200 mg/day total), increasing to 1200 mg twice daily (2400 mg/day total) as tolerated 3.
The pediatric literature, while more limited, supports this conservative approach with excellent safety profile 3, 4. A case report of a 17-year-old male demonstrated dramatic improvement at this dosing regimen over 6 months 3.
Key Clinical Considerations
Timing of response: Do not abandon treatment prematurely. Significant improvement typically begins at 9 weeks, not earlier 2. This is a critical pitfall—patients and providers may discontinue therapy too early if expecting rapid response.
Side effects: NAC is remarkably well-tolerated with predominantly mild gastrointestinal effects when they occur 1, 2, 5. One case of severe aggression in a child has been reported, warranting monitoring in pediatric populations 5.
Treatment duration: The evidence base uses 12-week trials, but case reports suggest continued benefit with longer treatment (up to 6-8 months) 3, 5.
Mechanism and Rationale
NAC works by restoring extracellular glutamate concentration in the nucleus accumbens, thereby reducing compulsive behaviors 1, 2. This glutamatergic modulation represents a fundamentally different mechanism than SSRIs, which have shown inconsistent results in these disorders 5.
Practical Implementation
Bold recommendation: Start all adult patients at 1200 mg/day divided into two doses, increase to 2400 mg/day by week 2-3, and consider pushing to 3000 mg/day if partial response at 9 weeks. Maintain treatment for at least 12 weeks before declaring failure.
For pediatric patients, use the lower end of the dosing range (1200-2400 mg/day) and monitor more closely for behavioral changes, though these are rare 3, 4.
NAC represents an accessible, over-the-counter option with Level 1 evidence supporting its use 1, 2, making it a reasonable first-line pharmacological intervention for both conditions, particularly given the lack of FDA-approved alternatives 6, 7.